Alan W Chiemprabha, MD | |
1070 Vinehaven Dr, Concord, NC 28025 | |
(704) 783-1840 | |
(704) 783-1850 |
Full Name | Alan W Chiemprabha |
---|---|
Gender | Male |
Speciality | Gastroenterology |
Experience | 26 Years |
Location | 1070 Vinehaven Dr, Concord, North Carolina |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1356350227 | NPI | - | NPPES |
P00205325 | Other | NC | RAILROAD MEDICARE |
89136HK | Medicaid | NC | |
136HK | Other | NC | BLUE CROSS BLUE SHEILD |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207RG0100X | Internal Medicine - Gastroenterology | (North Carolina) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
Carolinas Medical Center-northeast | Concord, NC | Hospital |
Carolinas Medical Center/behav Health | Charlotte, NC | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Cabarrus Gastroenterology Associates Pllc | 9436059649 | 34 |
News Archive
Tikcro Technologies today announced that the United States ("US") Department of Health and Human Services ("HHS") has granted orphan drug status to BioCancell's BC-819 drug, currently in Phase I/IIa clinical trials, for its use in treating ovarian cancer.
In the first study to investigate driving as it relates to teens with a high-functioning autism disorder (HFASD), child development and teen driving experts at The Children's Hospital of Philadelphia's Center for Child Injury Prevention Studies found that two-thirds of teenagers with a high-functioning autism spectrum disorder (HFASD) who are of legal driving age in their state are currently driving or plan to drive.
A form of cell communication called hedgehog signaling is vital for embryonic development in mammals.
In research that could ultimately lead to many new medicines, scientists from the Florida campus of The Scripps Research Institute (TSRI) have developed a potentially general approach to design drugs from genome sequence. As a proof of principle, they identified a highly potent compound that causes cancer cells to attack themselves and die.
New early data showed that an investigational device that specifically targets rapidly growing cancer cells with intermediate frequency electrical fields - called Tumor-Treating Fields (TTFields) - more than doubled the median overall survival rates in patients with recurrent glioblastoma multiforme (GBM), the most common and aggressive type of malignant brain tumor.
› Verified 3 days ago
Entity Name | Cabarrus Gastroenterology Associates Pllc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1780790592 PECOS PAC ID: 9436059649 Enrollment ID: O20040113000342 |
News Archive
Tikcro Technologies today announced that the United States ("US") Department of Health and Human Services ("HHS") has granted orphan drug status to BioCancell's BC-819 drug, currently in Phase I/IIa clinical trials, for its use in treating ovarian cancer.
In the first study to investigate driving as it relates to teens with a high-functioning autism disorder (HFASD), child development and teen driving experts at The Children's Hospital of Philadelphia's Center for Child Injury Prevention Studies found that two-thirds of teenagers with a high-functioning autism spectrum disorder (HFASD) who are of legal driving age in their state are currently driving or plan to drive.
A form of cell communication called hedgehog signaling is vital for embryonic development in mammals.
In research that could ultimately lead to many new medicines, scientists from the Florida campus of The Scripps Research Institute (TSRI) have developed a potentially general approach to design drugs from genome sequence. As a proof of principle, they identified a highly potent compound that causes cancer cells to attack themselves and die.
New early data showed that an investigational device that specifically targets rapidly growing cancer cells with intermediate frequency electrical fields - called Tumor-Treating Fields (TTFields) - more than doubled the median overall survival rates in patients with recurrent glioblastoma multiforme (GBM), the most common and aggressive type of malignant brain tumor.
› Verified 3 days ago
Mailing Address | Practice Location Address |
---|---|
Alan W Chiemprabha, MD 1070 Vinehaven Dr, Concord, NC 28025 Ph: (704) 783-1840 | Alan W Chiemprabha, MD 1070 Vinehaven Dr, Concord, NC 28025 Ph: (704) 783-1840 |
News Archive
Tikcro Technologies today announced that the United States ("US") Department of Health and Human Services ("HHS") has granted orphan drug status to BioCancell's BC-819 drug, currently in Phase I/IIa clinical trials, for its use in treating ovarian cancer.
In the first study to investigate driving as it relates to teens with a high-functioning autism disorder (HFASD), child development and teen driving experts at The Children's Hospital of Philadelphia's Center for Child Injury Prevention Studies found that two-thirds of teenagers with a high-functioning autism spectrum disorder (HFASD) who are of legal driving age in their state are currently driving or plan to drive.
A form of cell communication called hedgehog signaling is vital for embryonic development in mammals.
In research that could ultimately lead to many new medicines, scientists from the Florida campus of The Scripps Research Institute (TSRI) have developed a potentially general approach to design drugs from genome sequence. As a proof of principle, they identified a highly potent compound that causes cancer cells to attack themselves and die.
New early data showed that an investigational device that specifically targets rapidly growing cancer cells with intermediate frequency electrical fields - called Tumor-Treating Fields (TTFields) - more than doubled the median overall survival rates in patients with recurrent glioblastoma multiforme (GBM), the most common and aggressive type of malignant brain tumor.
› Verified 3 days ago
Dr. Vinay Patel, M.D. Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 1070 Vinehaven Dr Ne, Concord, NC 28025 Phone: 704-783-1840 Fax: 704-783-1850 | |
Aishwarya Palwai, MD Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 920 Church St N, Concord, NC 28025 Phone: 704-403-1311 | |
Meghan Rebecca Steiner, MD Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 100 Medical Park Dr, Ste 110, Concord, NC 28025 Phone: 704-403-1370 | |
Ashley Noisette Green, MD Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 200 Medical Park Dr, Ste 330, Concord, NC 28025 Phone: 704-403-1308 | |
Stephen Sean Zouzoulas, MD Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 100 Medical Park Dr, Ste 210, Concord, NC 28025 Phone: 704-403-6100 | |
Dr. Ernest F Johnson Iii, MD Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 433 Copperfield Blvd Ne, Concord, NC 28025 Phone: 704-786-7770 Fax: 704-971-0035 | |
Thomas Cary Cameron, MD Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 1085 Ne Gateway Ct Ne, Ste 330, Concord, NC 28025 Phone: 704-403-8320 |